Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	88.57	111	136.49	39.66	12.69
Cash & Cash Equivalents	88.57	111	136.49	39.66	12.69
Cash Growth	-20.21%	-18.67%	244.11%	212.53%	20.98%
Other Current Assets	3.65	7.2	4.75	3.11	1.63
Total Current Assets	92.22	118.2	141.24	42.77	14.32
Property, Plant & Equipment	0	0	0	0.04	0.08
Long-Term Investments	1.71	4.7	0	0	0
Goodwill and Intangibles	0	0	0	0.01	0.07
Other Long-Term Assets	2.32	0.64	0.02	0.02	0.02
Total Long-Term Assets	4.03	5.34	0.02	0.07	0.17
Total Assets	96.25	123.53	141.26	42.84	14.49
Accounts Payable	0.81	2.97	1.72	1.59	0.29
Current Debt	0	0	0	0.02	0.04
Other Current Liabilities	4.43	2.6	1.41	14.06	0.99
Total Current Liabilities	5.24	5.57	3.13	15.67	1.32
Long-Term Debt	0	0	0	0	0.01
Total Long-Term Liabilities	0	0	0	0	0.01
Total Liabilities	5.24	5.57	3.13	15.67	1.33
Total Debt	0	0	0	0.02	0.05
Debt Growth	-	-	-	-64.34%	-
Retained Earnings	-186.29	-156.19	-129.23	-111.9	-94.07
Shareholders' Equity	91.02	117.96	138.14	27.17	13.16
Net Cash / Debt	88.57	111	136.49	39.65	12.64
Net Cash / Debt Growth	-20.21%	-18.67%	244.26%	213.64%	20.50%
Net Cash Per Share	0.70	0.88	1.17	3.51	1.49
Working Capital	86.98	112.63	138.11	27.1	13
Book Value Per Share	0.72	0.93	1.18	2.40	1.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).